SARS-CoV-2 Neutralizing Human Monoclonal Antibodies

Monoclonal antibodies to SARS-CoV2 for use in COVID-19 diagnostics and therapeutics.

Key Benefits
Demonstrably neutralizing, important for therapeutic mAbs.
Most bind both RBG and stalk portion of spike protein, useful in case SARS-CoV2 strains develop variation in RBD.
Market Summary
Monoclonal antibodies (mAb) are derived from infected or previously infected patients whose B cells have responded to the infection by generating antibodies that bind to the virus. Researchers at Emory University have derived 4 mAb that demonstrated binding ability to the spike protein in vitro and 3 of the mAb demonstrated neutralizing capacity. The described mAb will contribute to or follow the expected trend of the global market for COVID-19 diagnostics, which is expected to reach $195.133 billion by 2027 from $60.322 billion in 2020 with a CAGR of 155 FROM 2021-2027 (BCC Research MDS015A).

Technical Summary
The invention consists of a novel method for the generation of monoclonal antibodies (mAb) for the purpose of being administered to SARS-CoV2 patients. During SARS-CoV2 infection mAb has the potential to neutralize the virus by blocking its receptor binding domain. Researchers generated a panel of 4 mAb from patients who were currently infected by or recovering from SARS-CoV2. The researchers then tested the mAB for their binding affinity to SARS-CoV2 spike proteins and their ability to neutralize the virus in vitro. All 4 mAB demonstrated successful binding ability to SARS-CoV2 spike proteins and its receptor binding domain. Furthermore, 3 of the mAb demonstrated neutralizing capacity.

Developmental Stage


Contact Information

TTO Home Page:

Name: David Mudd

Title: Licensing Associate